Quantitative Fluid Biomarkers for Precision Neurodegenerative Trials: From p-tau217 to Neurofilament Light
- Using plasma p-tau217 as a prognostic tool to enable early detection of pathological changes and improve trial enrichment and patient stratification
- Implementing neurofilament light (NfL) as a progression biomarker to provide scalable, blood-based measure of neuronal damage and support monitoring of disease-modifying effects
- Boosting regulatory confidence with multi-omic biomarker panels to integrate proteomics, immunoassays, and CSF–blood correlations to deliver robust endpoints